Kallyope

company

About

Kallyope is a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis.

  • 101 - 250

Details

Last Funding Type
Series D
Last Funding Money Raised
$236M
Industries
Biotechnology,Health Care,Medical,Pharmaceutical
Founded date
Jan 1, 2015
Number Of Employee
101 - 250
Operating Status
Active

Kallyope, headquartered at the Alexandria Center® for Life Science in New York City, is a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company’s cross-disciplinary team integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that leads to transformational therapeutics to improve human health. The company’s founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D., and Nobel laureate Richard Axel, M.D. For more information, visit www.kallyope.com.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$236M
Kallyope has raised a total of $236M in funding over 2 rounds. Their latest funding was raised on Feb 15, 2022 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 15, 2022 Series D $236M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Kallyope is funded by 1 investors. Hartford HealthCare Endowment are the most recent investors.
Investor Name Lead Investor Funding Round
Hartford HealthCare Endowment Series D